{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:33:49Z","timestamp":1742938429664,"version":"3.40.3"},"publisher-location":"Cham","reference-count":22,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030215736"},{"type":"electronic","value":"9783030215736"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-21573-6_72-1","type":"book-chapter","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:03:41Z","timestamp":1599131021000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hematopoietic Growth Factors"],"prefix":"10.1007","author":[{"given":"Ana Catarina","family":"Silva","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o Nuno","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Manuel","family":"Sousa Lobo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"72-1_CR1","unstructured":"(EMA), E.M.A (2009a) EPAR summary for the public: Eporatio - epoetin theta. Available from: \n              https:\/\/www.ema.europa.eu\/en\/documents\/overview\/eporatio-epar-summary-public_en.pdf"},{"key":"72-1_CR2","unstructured":"(EMA), E.M.A (2009b) EPAR summary for the public: Biopoin - epoetin theta. Available from: \n              https:\/\/www.ema.europa.eu\/en\/documents\/overview\/biopoin-epar-summary-public_en.pdf"},{"key":"72-1_CR3","unstructured":"(EMA), E.M.A (2012) EPAR summary for the public: Mircera - methoxy polyethylene glycol-epoetin beta. Available from: \n              https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mircera-epar-summary-public_en.pdf"},{"key":"72-1_CR4","unstructured":"(EMA), E.M.A (2015a) Public summary of opinion on orphan designation: filgrastim for the treatment of amyotrophic lateral sclerosis. Available from: \n              https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/08\/532-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-amyotrophic-lateral_en.pdf"},{"key":"72-1_CR5","unstructured":"(EMA), E.M.A (2015b) Public summary of opinion on orphan designation: filgrastim for the treatment of spinal cord injury. Available from: \n              https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/08\/580-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-spinal-cord-injury_en.pdf"},{"key":"72-1_CR6","unstructured":"(EMA), E.M.A (2015c) EPAR summary for the public: NeoRecormon - epoetin beta. Available from: \n              https:\/\/www.ema.europa.eu\/en\/documents\/overview\/neorecormon-epar-summary-public_en.pdf"},{"key":"72-1_CR7","unstructured":"(EMA), E.M.A (2016) Public summary of opinion on orphan designation: molgramostim for the treatment of acute respiratory distress syndrome. Available from: \n              https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/16\/1685-public-summary-opinion-orphan-designation-molgramostim-treatment-acute-respiratory-distress_en.pdf"},{"key":"72-1_CR8","unstructured":"(FDA), F.D.A (2017a) Information for Epogen\/Procrit (Epoetin alfa). Available from: \n              https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm541173.htm"},{"key":"72-1_CR9","unstructured":"(FDA), F.D.A (2017b) Information for Aranesp (darbepoetin alfa). Available from: \n              https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm541148.htm"},{"key":"72-1_CR10","unstructured":"(FDA), F.D.A (2017c) Leukine (sargramostim)US License 1752. Available from: \n              https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103362s5237lbl.pdf"},{"key":"72-1_CR11","unstructured":"(FDA), F.D.A (2018a) FDA approves Mircera for anemia associated with chronic kidney disease in pediatric patients on dialysis. Available from: \n              https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm610210.htm"},{"key":"72-1_CR12","unstructured":"(FDA), F.D.A (2018b). \n              https:\/\/www.fda.gov\/EmergencyPreparedness\/Counterterrorism\/MedicalCountermeasures\/MCMIssues\/ucm602102.htm\n              \n            . Available from: \n              https:\/\/www.fda.gov\/EmergencyPreparedness\/Counterterrorism\/MedicalCountermeasures\/MCMIssues\/ucm602102.htm"},{"issue":"31","key":"72-1_CR13","doi-asserted-by":"publisher","first-page":"22421","DOI":"10.1074\/jbc.M604644200","volume":"281","author":"J Chen","year":"2006","unstructured":"Chen J, C\u00e1rcamo JM, Golde DW (2006) The \u03b1 subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-kit and inhibits c-kit signaling. J Biol Chem 281(31):22421\u201322426","journal-title":"J Biol Chem"},{"key":"72-1_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.exphem.2016.10.008","volume":"46","author":"P Dwivedi","year":"2017","unstructured":"Dwivedi P, Greis KD (2017) Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Exp Hematol 46:9\u201320","journal-title":"Exp Hematol"},{"issue":"12","key":"72-1_CR15","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.exphem.2008.08.003","volume":"36","author":"S Elliott","year":"2008","unstructured":"Elliott S, Pham E, Macdougall IC (2008) Erythropoietins: a common mechanism of action. Exp Hematol 36(12):1573\u20131584","journal-title":"Exp Hematol"},{"issue":"21","key":"72-1_CR16","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1056\/NEJM198911233212106","volume":"321","author":"JE Groopman","year":"1989","unstructured":"Groopman JE, Molina J-M, Scadden DT (1989) Hematopoietic growth factors. N Engl J Med 321(21):1449\u20131459","journal-title":"N Engl J Med"},{"issue":"19","key":"72-1_CR17","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1056\/NEJMra052706","volume":"354","author":"K Kaushansky","year":"2006","unstructured":"Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354(19):2034\u20132045","journal-title":"N Engl J Med"},{"issue":"2","key":"72-1_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jps.24243","volume":"104","author":"T Lipi\u00e4inen","year":"2015","unstructured":"Lipi\u00e4inen T et al (2015) Formulation and stability of cytokine therapeutics. J Pharm Sci 104(2):307\u2013326","journal-title":"J Pharm Sci"},{"key":"72-1_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/978-3-030-00710-2_24","volume-title":"Pharmaceutical biotechnology: fundamentals and applications","author":"JJ P\u00e9rez-Ruixo","year":"2019","unstructured":"P\u00e9rez-Ruixo JJ (2019) Hematopoietic growth factors. In: Crommelin DJA, Sindelar RD, Meibohm B (eds) Pharmaceutical biotechnology: fundamentals and applications. Springer International Publishing, Cham, pp 521\u2013535"},{"issue":"1","key":"72-1_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.drudis.2018.09.011","volume":"24","author":"SB Santos","year":"2019","unstructured":"Santos SB, Lobo JMS, Silva AC (2019) Biosimilar medicines used for cancer therapy in Europe: a review. Drug Discov Today 24(1):293\u2013299","journal-title":"Drug Discov Today"},{"key":"72-1_CR21","doi-asserted-by":"crossref","unstructured":"Silva A.C., Lobo J.M.S. (2019) Cytokines and Growth Factors. In: Silva A.C., Moreira J.N., Lobo J.M.S., Almeida H. (eds) Current Applications of Pharmaceutical Biotechnology. Advances in Biochemical Engineering\/Biotechnology, vol 171. Springer, Switzerland.","DOI":"10.1007\/10_2019_105"},{"key":"72-1_CR22","volume-title":"Pharmaceutical biotechnology: concepts and applications","author":"G Walsh","year":"2013","unstructured":"Walsh G (2013) Pharmaceutical biotechnology: concepts and applications. Wiley, London"}],"container-title":["Encyclopedia of Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-21573-6_72-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:13:44Z","timestamp":1599131624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-21573-6_72-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030215736","9783030215736"],"references-count":22,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-21573-6_72-1","relation":{},"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"1 April 2020, 00:00:00","order":1,"name":"received","label":"Received","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"8 April 2020, 00:00:00","order":2,"name":"accepted","label":"Accepted","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"10 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}